Axway Global Study Reveals Gap Between Impact of Technology on Personal and Professional Lives
To examine the impact of technology on our lives, Axway (Paris:AXW) (Euronext: AXW.PA), a catalyst for digital transformation, today published the results of a global survey which found that 91 percent of people believe that technology advancements have made their lives easier. The survey of more than 2,600 people across the Australia, France, Germany, United States, and the United Kingdom identified a huge gap between the impact of technology on our personal and professional lives and also examined the concerns people have around the changing relationship between man and machine.
Organizations Need to Keep Up with Technology Used in Consumer’s Personal Lives
Despite huge investments from organizations across almost every industry in technologies that transform business processes and enable new models for working, the survey found that technology is having a much larger impact on our personal lives.
- 70 percent of consumers stated that technology has had a greater impact on their personal lives than their professional lives.
- This trend was particularly evident with millennials, with 75 percent of millennials versus older generations (66 percent) stating that their personal lives have been impacted more by technology.
Technology Improves Our Lives, But Impacts Interpersonal Skills
Despite the vast majority of people (91 percent) agreeing that technology has had a positive impact on our lives, whether in the personal or professional realm, the survey identified key concerns around its impact on our interpersonal skills. The top concerns were:
- 53 percent said that today’s level of interaction with technology is killing the art of good conversation, with women (56 percent) more likely than men (49 percent).
- 40 percent said technology is making people more impatient.
- 39 percent said that technology is reducing attention spans.
Blurring Line Between Man and Machine is Creating Concerns
As organizations continue to invest in new technologies and look to accelerate the impact of technology in the professional world, they need to carefully consider how new technologies can replicate human behavior such as artificial intelligence. These new technologies present a concern for 85 percent of consumers, with top concerns being:
- 34 percent worry about machines invading their privacy.
- 29 percent are concerned about machines taking over jobs.
- 21 percent, or one in five consumers, are concerned about machines taking over the world.
Further, with the rise of crypto currencies such as Bitcoin, technology will play an increasingly larger role in the future of payments made by humans.
- One in four consumers (23 percent) believe digital currency will most likely replace cash within the next 10-15 years.
Personalization vs. Privacy: Concerns Vary Across the World
New technologies capture huge volumes of personal data that organizations use to develop, market and sell their products and services. The vast majority of respondents (83 percent) are concerned about how organizations use their personal data.
- 53 percent do not like the idea of organizations having their personal information. Consumers in Australia (59 percent) and the U.S. (55 percent) are most concerned, while respondents in France (44 percent) are the least concerned.
- Only 27 percent like it when organizations use data to personalize products and services. Opinions on personalization varied significant across countries, with respondents France (38 percent) valuing it more than any other country and respondents in Australia (20 percent) seeing the least value.
“In 2017, we saw technology continue to evolve at a rapid pace as innovations such as artificial intelligence, the Internet of Things, block chain and augmented reality started to reach the mainstream,” said Vince Padua, Chief Innovation and Technology Officer at Axway. “These technologies are quickly transforming the relationship between man and machine and are ultimately making our lives easier. However, this study reveals that the competitive pressure and digital disruption are increasing, and using the right technology is necessary to gain the upper hand. Looking ahead to 2018, results from this survey will help inform how organizations can leverage technology to provide faster innovation, expand their digital business ecosystems and obtain higher levels of customer experience.”
About the Survey
Conducted by international research firm Research+Data Insights (RDI), the survey was fielded online and included participation from 2,653 adults in the US, France, UK, Australia and Germany. Respondents were a mix of male and female, ranging in age from 18 to 60 years old.
Axway (Euronext: AXW.PA) is a catalyst for transformation. With Axway AMPLIFY™, our cloud-enabled data integration and engagement platform, digital leaders anticipate, adapt and scale to meet rising customer expectations. Our unified, API-first approach connects data from anywhere, expands collaboration, fuels millions of apps and delivers real-time analytics to build customer experience networks. To learn more, visit www.axway.com.
Virginia Stratford, Tel. (415) 856-5120
Blanc & Otus
Om Business Wire
(c) 2018 Business Wire, Inc., All rights reserved.
Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.
Følg saker fra Business Wire
Registrer deg med din epostadresse under for å få de nyeste sakene fra Business Wire på epost fortløpende. Du kan melde deg av når som helst.
Siste saker fra Business Wire
Octapharma announces approval of new Nuwiq® product strengths in Europe, increasing dosing flexibility for patients with haemophilia A18.6.2018 07:06 | Pressemelding
Octapharma announced today that the European Medicines Agency (EMA) has approved an extension of marketing authorisation for its human cell line-derived recombinant factor VIII (rFVIII) product, Nuwiq®. New single dose vial strengths of 2500, 3000 and 4000 International Units (IU) will be available in Europe, in addition to the current strengths of 250, 500, 1000 and 2000 IU. The new Nuwiq® vial strengths have been available in the US since September last year, following approval by the FDA. Nuwiq® is indicated in adults and children of all ages for on-demand treatment and prophylaxis, including during surgery, to prevent and control bleeding episodes in patients with haemophilia A. This expanded array of vial strengths has the potential to increase treatment options for patients with haemophilia A by improving dosing flexibility. Patients who previously required more than one vial per infusion may be able to reduce the number of vials needed. Nuwiq® is the only rFVIII available in an
STATS and SpokeHub Partner to Power Deeper, More Meaningful Conversations Around the 2018 FIFA World Cup18.6.2018 07:00 | Pressemelding
Today, STATS, the worldwide leader in sports data and intelligence, and SpokeHub announced a new partnership to bring STATS Insights to SpokeHub’s social engagement platform, connecting worldwide World Cup football (soccer) fans with content that is more impactful. Download the app today to see the match scores, player insights, and engage with World Cup fans everywhere! STATS Insights leverages more than 37 years of research experience to deliver deep historical and comparative statistical insights, play-by-play descriptions and in-game trends based on events as they happen in the match. Before, during and after each match, SpokeHub will harness STATS Insights to amplify conversations among World Cup football communities. During the game, live Insights will deliver trends on players and teams based on in-game events, statistics and milestones. “No sporting event gets global attention like the World Cup, and every fan is looking for deeper analysis around their favorite teams and playe
Celltrion Completes Resubmission to FDA for Proposed Trastuzumab Biosimilar18.6.2018 02:53 | Pressemelding
Celltrion (KRX:068270) has made a resubmission to the FDA (U.S. Food and Drug Administration) to obtain its marketing approval for CT-P6, a proposed mAb biosimilar to Herceptin® (trastuzumab). Celltrion submitted its abbreviated Biologics License Applications (aBLAs) for CT-P10 and CT-P6 to the FDA in April and May of last year, respectively. However, it received CRLs (complete response letters) from the FDA related to the warning letter issued by the FDA in January 2018, related to the manufacturing facility in Incheon, South Korea. Celltrion had completed the resubmission for the approval of CT-P10, a proposed biosimilar to Rituxan® (rituximab) last month. In accordance with FDA regulations, the approval procedure will be usually finalized within six months from the resubmission, so Celltrion expects the approval for the U.S. market of the two proposed biosimilars within this calendar year. FDA has notified Celltrion of its re-inspection schedule regarding regular audit results, and
CES Asia: Innovation at the Speed of 5G15.6.2018 14:59 | Pressemelding
CES Asia® 2018 wrapped today with the rapid pace of global innovation front and center over the show’s three day duration. The next stage of technology advancements were showcased across vehicle tech, robotics, artificial intelligence (AI), virtual and augmented reality, digital health and more. The event, 24 percent larger than last year in terms of footprint, cemented itself as the place to fully experience how the pace of technology is accelerating globally. CES Asia, the premier event for tech innovation in the Asian marketplace, will return to Shanghai, China, June 11-13, 2019. “5G and AI are igniting growth across the entire tech ecosystem changing the way we interact with technology and the world around us,” said Gary Shapiro, president and CEO, Consumer Technology Association (CTA)™. “It’s incredible to see technology refining and reinventing itself at such a fast pace. Just six months ago we were at CES with life-altering tech all around us. This week, I saw that technology re
bluebird bio Presents New Data from Northstar (HGB-204) and Northstar-2 (HGB-207) Studies of LentiGlobin™ Gene Therapy in Patients with Transfusion-Dependent β-Thalassemia at Annual Congress of the European Hematology Association15.6.2018 10:00 | Pressemelding
bluebird bio, Inc. (Nasdaq: BLUE) announced that new data from the completed Phase 1/2 Northstar (HGB-204) study in adolescents and adults with transfusion-dependent β-thalassemia (TDT) and any genotype, and its ongoing, Phase 3 Northstar-2 (HGB-207) multicenter clinical study of LentiGlobin™ investigational gene therapy in patients with TDT and non-β0/β0 genotypes, will be presented in an oral session on June 16 at the 23rd Annual Congress of the European Hematology Association by Franco Locatelli, M.D., Ph.D., of the IRCCS Ospedale Pediatrico Bambino Gesù of Rome, Italy. “The maturing data from HGB-204 and HGB-207 suggest that one-time treatment with LentiGlobin may address the underlying genetic cause of TDT. With our refined manufacturing process, the majority of patients with TDT and non-β0/β0 genotypes are transfusion-free and producing total hemoglobin at normal or near-normal levels,” said David Davidson, M.D., chief medical officer, bluebird bio. “We are on track to submit a m
bluebird bio Announces New Interim Data from Phase 1 (HGB-206) Study of LentiGlobin™ Gene Therapy in Patients with Severe Sickle Cell Disease at Annual Congress of the European Hematology Association15.6.2018 10:00 | Pressemelding
bluebird bio, Inc. (Nasdaq: BLUE) today announced new interim data from the ongoing HGB-206 Phase 1 multicenter clinical study of LentiGlobin investigational gene therapy in patients with severe sickle cell disease (SCD) will be presented in an oral presentation on Saturday, June 16 at the 23rd Congress of the European Hematology Association (EHA) by Julie Kanter, M.D., Medical University of South Carolina, Charleston, South Carolina. “The consistent production of increased amounts of anti-sickling HbAT87Q in the Group C patients reflects the substantial positive impact of the changes introduced with the amended HGB-206 study protocol and refined manufacturing process. All four Group C patients with greater than or equal to three months follow-up are making over 30 percent anti-sickling HbAT87Q. The first patient treated, now with six months of follow-up, is producing over 60 percent anti-sickling HbAT87Q with a normal total hemoglobin level of 14.2 g/dL,” said David Davidson, M.D., ch